Novo Nordisk has settled a patent infringement lawsuit against telehealth company Hims & Hers regarding the sale of compounded Wegovy. As part of the agreement, Hims will cease advertising compounded GLP-1 products but will continue to offer them if deemed clinically necessary by a provider. Additionally, Hims will now list brand-name Wegovy on its platform, marking a shift in its business strategy.